Evidence of diminished FEV1 and FVC in 6-year-olds followed in the European cystic fibrosis patient registry, 2007–2009  by VanDevanter, Donald R. & Pasta, David J.
www.elsevier.com/locate/jcf
Journal of Cystic Fibrosis 12 (2013) 786–789Short Communication
Evidence of diminished FEV1 and FVC in 6-year-olds followed in the
European cystic ﬁbrosis patient registry, 2007–2009
Donald R. VanDevanter a,⁎, David J. Pasta b
a Case Western Reserve University School of Medicine, Cleveland, OH, United States
b ICON Late Phase & Outcomes Research, San Francisco, CA, United States
Received 3 February 2013; received in revised form 19 March 2013; accepted 9 April 2013
Available online 28 April 2013Abstract
Background: Many infants with cystic ﬁbrosis (CF) exhibit airway inﬂammation, gas trapping, bronchiectasis, and/or reduced ﬂow, but by age
6 years have forced vital capacities (FVC) and expiratory volumes in 1 second (FEV1) within the variability range of the normal population. We
sought evidence of diminished FVC and FEV1 in 6-year-olds with CF.
Methods: GLI 2012 FVC and FEV1 Z-scores for 6-year-olds from the European CF Patient Registry were plotted against theoretical values from
the Normal distribution.
Results:Mean FVC and FEV1 Z-scores for 681 patients (322 females) were −0.43 (SD = 1.41) and −0.65 (1.40). Z-scores were consistently lower
than expected for the normative population by quantile–quantile plot.
Conclusions: Diminished FEV1, and to a lesser extent FVC, is found in a large majority of this population, consistent with an established body of
evidence that loss of lung function begins early in life for most, if not all, children with CF.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: FEV1; Early disease progression; Epidemiology; Infants1. Introduction
The advent of cystic fibrosis (CF) newborn screening has
produced CF infant populations largely lacking respiratory
signs and symptoms [1]. When asymptomatic infants with CF
are studied by bronchoalveolar lavage, high-resolution com-
puterized tomography (HRCT), and/or infant pulmonary
function testing, large proportions have important markers of
early CF lung disease such as elevated airway inflammation,
gas trapping, bronchiectasis, and/or reduced flow [1–5].
However, a majority of 6-year-olds with CF have forced
expiratory volumes in 1 second (FEV1) and forced vital
capacities (FVC) well within the bounds of normal variability
of the unaffected population. The apparent paradox of⁎ Corresponding author at: 12520 33rd Street Ct E, Edgewood, WA 98372,
United States. Tel.: +1 253 3705859.
E-mail address: enigmaster@comcast.net (D.R. VanDevanter).
1569-1993/$ -see front matter © 2013 European Cystic Fibrosis Society. Published
http://dx.doi.org/10.1016/j.jcf.2013.04.005widespread early lung disease in infants with CF but essentially
‘normal’ lung function in 6-year-olds as measured by FVC and
FEV1 creates a conundrum: are asymptomatic infants with CF
appropriate candidates for chronic respiratory treatments
targeted at lung disease progression or not? We have analyzed
FEV1 % predicted, FVC % predicted, and associated Z-scores
for 6-year-olds followed at CF care centers in Europe for
evidence that diminished lung function extends beyond the
minority of children with CF with ‘abnormally low’ FVC and/
or FEV1 values and into the larger population with values
within the normal range of variability for a healthy population.
2. Methods
Patients with CF included in this analysis were cared for in
an ECFS member country that had supplied FEV1 and FVC
data to the European CF Registry for each year from 2007 to
2009. Only countries that had agreed to contribute patient databy Elsevier B.V. All rights reserved.
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Fig. 1. Distributions of FVC and FEV1 Z-scores and theoretical Z-scores among
681 6–year-olds followed in the ECFS Registry between 2007 and 2009. Gray
circles represent FVC Z-scores, black circles represent FEV1 Z-scores, and open
circles represent theoretical Z-scores derived from the Normal distribution.
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have FEV1 and FVC measures (liters) and accompanying
height (cm), age (years), and sex available between their 6th
and 7th birthdays.
Global Lung Function Initiative (GLI) 2012 FEV1 %
predicted, FVC % predicted, FEV1/FVC, and associated
Z-scores were determined for each patient using Microsoft
Excel 2007 and a macro downloaded from http://www.
lungfunction.org [6]. Patient race, which is not tracked in the
ECFS Patient Registry, was assumed to be Caucasian.
Observed Z-score distributions for the study population were
plotted against the Normal distribution and observed Z-scores
were plotted against theoretical Z scores derived from the
Normal distribution in quantile–quantile plots.
3. Results
A total of 681 patients (322 females, 359 males) from Austria,
Belgium, Czech Republic, Germany, Denmark, France, Greece,
Hungary, Israel, Italy, The Netherlands, Portugal, and Slovenia
were included in analyses. In all, 51.1% of 6-year-old CF patients
followed in their respective National Patient Registries between
2007 and 2009 had required data available and were included.
Slightly more patients were included from 2007 (253) than from
2008 (215) and 2009 (211) (Table 1) due to a steadily decreasing
availability of complete records (54.4%, 50.3%, and 48.4%) over
the period.
The mean FEV1 for the study population was 91.6 ± 17.9%
predicted (±SD), corresponding to a mean Z score of −0.65 ±
1.40 (Table 1). Mean FEV1 Z-scores were not different for
females (−0.65 ± 1.42) and males (−0.64 ± 1.39), but varied
by year: −0.66 ± 1.37 for 2007, −0.75 ± 1.42 for 2008, and
−0.53 ± 1.43 for 2009 (Table 1), with the increase observed
between 2007 and 2009 not statistically significant (P = 0.32).
The mean FEV1/FVC ratio for the population was 0.87 ± 0.09,
corresponding to a mean Z-score of −0.36 ± 1.36. In all, 151
patients (22.2%) had FEV1 Z-scores b −1.645, the lower limit of
normal (LLN), more than four times as many as the 34 patients
(5%) anticipated if the population followed the Normal
distribution (Fig. 1). The mean FVC Z-score was −0.43 ± 1.41
(Table 1), with 118 patients (17.2%) having FVC Z-scores below
the LLN (Fig. 1).
Distributions of FVC and FEV1 Z scores by sex were
comparable, with FEV1 Z-scores tending to be lower than FVC
Z-scores (Table 1, Fig. 1). When analyzed by quantile–quantileTable 1
Study population characteristics by year and sex.
2007
Cohort
(N = 253)
2008
Cohort
(N = 217)
Females, N (%) 122 (48.2%) 111 (51.2%)
Mean age, yrs (SD) 6.34 (0.25) 6.31 (0.24)
Mean FEV1 % predicted (SD) 91.5 (17.5) 90.4 (18.0)
Mean FEV1 Z-score (SD) −0.66 (1.37) −0.75 (1.42)
Mean FVC % predicted (SD) 94.7 (17.6) 93.6 (17.6)
Mean FVC Z-score (SD) −0.43 (1.40) −0.51 (1.39)plot, Z-scores for both FVC and FEV1 were consistently lower
than would have been anticipated from random sampling of
‘healthy’ populations (Fig. 2).
4. Discussion
FEV1 % predicted is commonly used to stratify CF lung
disease stage in children old enough to reliably perform
spirometry [7]. This has proven to be useful, as FEV1 %
predicted has been shown to be a significant risk factor for
morbidity [8] and mortality [9] and a surrogate for demonstra-
tion of efficacy for chronic CF respiratory therapies [10].
However, it has been demonstrated that FEV1 is a relatively
insensitive measure of early CF lung disease (with FVC less
sensitive still) [11], as the incidence of abnormal findings by
HRCT or multiple breath washout far exceed those by
spirometry among school age children with CF [12].
An unfortunate and unintended consequence of using FEV1
% predicted to stratify CF lung disease stage is that some CF
clinicians might mistakenly conclude that a majority of the
77.8% of 6-year-olds with CF and FEV1 Z-scores above the
LLN in our study had no evidence of lung disease, and thus
warranted observation but not necessarily intervention. How-
ever, quantile–quantile plots (Fig. 2) suggest that both FVC and
FEV1 Z-scores of almost our entire population of 6-year-olds
with CF were shifted to lower values, a result that would
suggest that most, if not all, of these children already had
diminished FVC and FEV1 and had experienced some level of
CF lung disease. In addition, evidence of modest obstruction in2009
Cohort
(N = 211)
Female
Cohort
(N = 322)
Male
Cohort
(N = 359)
All (N = 681)
89 (42.2%) – – 322 (47.3%)
6.34 (0.25) 6.33 (0.24) 6.34 (0.25) 6.33 (0.25)
93.1 (18.2) 91.6 (18.0) 91.7 (17.8) 91.6 (17.9)
−0.53 (1.43) −0.65 (1.42) −0.64 (1.39) −0.65 (1.40)
95.8 (18.3) 94.7 (17.7) 94.7 (18.0) 94.7 (17.8)
−0.34 (1.45) −0.44 (1.40) −0.42 (1.42) −0.43 (1.41)
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Fig. 2. Quantile–quantile plot of observed FVC and FEV1 Z-scores among 681
6–year-olds followed in the ECFS Patient Registry between 2007 and 2009 by
theoretical Z-scores derived from the Normal distribution. Gray circles
represent FVC Z-scores and black triangles represent FEV1 Z-scores. Dashes
mark line of identity.
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−0.36. This interpretation is consistent with the previously
reported prevalence of risk factors in early childhood that have
been associated with diminished FEV1 at age 6 years [13], as
well as previous observations that markers of early lung disease
such as inflammation, gas trapping, and reduced flow are
relatively common in CF infants [1–5]. Further, longitudinal
studies have confirmed that reduced flow in infants with CF
persists through school age [14], that reduced FEV1 in
school-age children is predicted by ventilation inhomogeneity
in younger children with CF [15], and that small airway disease
can be detected by forced expiratory flow at 75% of FVC
(FEF75) before substantial changes in FEV1 are observed in
young children with CF [11].
Our analysis was limited by an inability to analyze FVC and
FEV1 Z-scores for all 6-year-olds with CF in the countries
studied due to incomplete data availability, and we cannot
unequivocally state that inclusion of all 6-year-olds would not
have affected our results. FEF75 Z-score distributions, whichwere not available for these patients, would have been useful to
confirm our observations of a general shift to worse spirometric
measures. In addition, use of GLI 2012 normative equations
may be an imperfect substitute for case-controlled studies of
spirometry Z-scores of 6-year-olds in specific geographic
regions. However, we feel that our general conclusion, that an
FVC or FEV1 within the normal range of variability is
insufficient to establish that a 6-year-old child with CF has
not already experienced diminished lung function, is unaffected
by these limitations.
Our observations suggest that respiratory interventions
intended to preserve lung function should not be limited to
infants with CF who displays signs and symptoms of lung
disease and 6-year-olds with ‘abnormal’ FVC and/or FEV1, but
rather should be considered more universally to improve
outcomes. Analyses using quantile–quantile plots of FVC and
FEV1 Z-scores in school-age children with CF may prove
useful in the future in evaluating the success of earlier
intervention efforts.
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